Design of TLR2-ligand-synthetic long peptide conjugates for therapeutic vaccination of chronic HBV patients

Synthetic long peptide (SLP) vaccination is a promising new treatment strategy for patients with a chronic hepatitis B virus (HBV) infection. We have previously shown that a prototype HBV-core protein derived SLP was capable of boosting CD4+ and CD8+ T cell responses in the presence of a TLR2-ligand...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antiviral research 2020-06, Vol.178, p.104746-104746, Article 104746
Hauptverfasser:	Dou, Yingying, Jansen, Diahann T.S.L., van den Bosch, Aniek, de Man, Robert A., van Montfoort, Nadine, Araman, Can, van Kasteren, Sander I., Zom, Gijs G., Krebber, Willem-Jan, Melief, Cornelis J.M., Woltman, Andrea M., Buschow, Sonja I.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic Antigen Presentation CD4-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - immunology Chronic HBV infection Cross-presentation Cross-Priming Dendritic Cells - immunology Epitopes, T-Lymphocyte Hepatitis B Core Antigens - immunology Hepatitis B Core Antigens - metabolism Hepatitis B Vaccines - immunology Hepatitis B Vaccines - therapeutic use Hepatitis B virus Hepatitis B virus - immunology Hepatitis B, Chronic - immunology Hepatitis B, Chronic - therapy Humans Immunotherapy Ligands Synthetic long peptide T-Lymphocytes - immunology TLR2-Ligand Toll-Like Receptor 2 - immunology Toll-Like Receptor 2 - metabolism Vaccines, Subunit - immunology Vaccines, Subunit - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!